Mevion

US-based MedStar Georgetown University Hospital has secured final approval to commence the construction of a new proton therapy facility at its Lombardi Comprehensive Cancer Center in Washington DC.

Construction of the new centre is expected to start later this year. Once complete, Mevion Medical Systems will install the MEVION S250 proton therapy system at the centre.

Installation of the system is planned for completion in 2016.

MedStar Georgetown University Hospital president Richard Goldberg said: "The addition of proton therapy to our experienced and internationally known cancer programme is a natural progression for us as the only provider in the region with a long history of serving both children as well as adults with cancer.

"We are excited to bring this important technology to our community and to give our patients yet another cutting-edge cancer treatment option."

The MEVION S250 system will be used in the treatment of adult and paediatric cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Proton therapy is a method used to treat a wide range of cancers in sensitive areas, including central nervous system, chest, head and neck, eye, and prostate.

Mevion Medical Systems president and CEO Joseph Jachinowski said: "The MEVION S250 proton therapy system provides a significant benefit to cancer patients while redefining the economics and accessibility of proton therapy.

"We are proud to bring the most advanced radiation therapy device to our nation’s capital and another leading healthcare institution."

MedStar, which is an acute-care teaching and research hospital with 609 beds, includes neurosciences, transplant, cancer and gastroenterology divisions.


Image: MedStar is to build a new proton therapy centre in Washington DC. Photo: courtesy of Business Wire.